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Activated macrophages undergo metabolic reprogramming which drives their 38	
pro-inflammatory phenotype, but the mechanistic basis for this remains 39	
obscure. Here we demonstrate that upon lipopolysaccharide (LPS) stimulation 40	
macrophages shift from producing ATP by oxidative phosphorylation to 41	
glycolysis, while also increasing succinate levels. We show that increased 42	
mitochondrial oxidation of succinate via succinate dehydrogenase (SDH) and 43	
an elevation of mitochondrial membrane potential combine to drive 44	
mitochondrial reactive oxygen species (ROS) production. RNA sequencing 45	
reveals that this combination induces a pro-inflammatory gene expression 46	
profile, while an inhibitor of succinate oxidation, dimethyl malonate (DMM), 47	
promotes an anti-inflammatory outcome. Blocking ROS production with 48	
rotenone, by uncoupling mitochondria, or by expressing the alternative 49	
oxidase (AOX) inhibits this inflammatory phenotype, with AOX protecting mice 50	
from LPS lethality. The metabolic alterations that occur upon activation of 51	
macrophages therefore repurpose mitochondria from ATP synthesis to ROS 52	




Macrophages have two key roles: to respond rapidly to infection and injury and then 57	
to help repair the tissue damage that occurs as a result of this response. This 58	
requires macrophages to initially adopt a pro-inflammatory phenotype and then later, 59	
when the immediate danger has passed, to acquire an anti-inflammatory phenotype 60	
to promote resolution and repair. The factors that drive and sustain these changes 61	
are not fully understood. However, multiple lines of evidence implicate alterations in 62	
mitochondrial function, reactive oxygen species (ROS) production and related 63	
metabolic pathways in this phenotypic switch (O'Neill and Pearce, 2016). For 64	
example, pro-inflammatory macrophages are more glycolytic, produce more ROS 65	
and accumulate succinate to a greater extent than resting macrophages (O'Neill and 66	
Pearce, 2016). Even so, the mechanisms and significance of these changes are 67	
obscure. The electron transport chain (ETC) is a major component of mitochondrial 68	
metabolism and resting macrophages utilize this efficient form of oxidative 69	
metabolism to generate ATP. However, once macrophages are activated (e.g. with 70	
the Toll-like receptor 4 (TLR4) agonist lipopolysaccharide (LPS)) oxidative 71	
phosphorylation is suppressed and cells favor glycolysis as an alternative, but less 72	
energetically efficient, mode of ATP generation (Tannahill et al., 2013). In dendritic 73	
cells (DCs) the switch to glycolysis and away from oxidative phosphorylation 74	
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supports fatty acid synthesis required for the expansion of organelles necessary for 75	
the production and secretion of key proteins essential for DC activation (Everts et al., 76	
2014) and to prevent apoptosis in the face of a lowered level of ATP production by 77	
oxidative phosphorylation (Everts et al., 2012). TLR4 stimulation will also lead to 78	
mitochondrial ROS generation from complex I through an unknown mechanism 79	
(West et al., 2011). On the other hand, activated T cells maintain oxidative 80	
phosphorylation in conjunction with glycolysis but whether oxidative metabolism is 81	
required for the production of biosynthetic precursors and ATP following stimulation 82	
or to generate a ROS signal is unclear (Sena et al., 2013). Here we set out to 83	
determine the mechanistic rationale underlying the mitochondrial, ROS and 84	
metabolic changes in macrophages that determine the inflammatory status of the 85	
cell, noting that all are linked by electron transfer in the ETC. We have found that 86	
following stimulation with LPS macrophages repurpose their mitochondria from ATP 87	
production to succinate-dependent ROS generation, with glycolysis taking on the role 88	
of ATP generation, enabling mitochondria to sustain a high membrane potential. 89	
Thus, the enhanced production of succinate is a critical regulator of the pro-90	
inflammatory response to LPS, both through the generation of ROS following 91	
oxidation by the ETC and also via HIF-1α stabilization. Concurrently, anti-92	
inflammatory gene expression is decreased. These events demonstrate a role for 93	
succinate oxidation by the ETC in the pro-inflammatory response to LPS and provide 94	
insights into the previously elusive mechanism by which macrophages generate 95	
mitochondrial ROS. We have identified a process whereby mitochondrial metabolism 96	
is intimately linked to the profound gene expression changes that occur in 97	





Succinate drives IL-1β production and limits the production of IL-1RA and IL-10 103	
 104	
Succinate is a well established pro-inflammatory metabolite which is known to 105	
accumulate during macrophage activation, the levels of which affect HIF-1α activity, 106	
a key transcription factor in the expression of pro-inflammatory genes (Tannahill et 107	
al., 2013). We therefore examined the effects of pretreatment of LPS-activated bone 108	
marrow derived macrophages (BMDMs) with cell-permeable diethyl succinate 109	
(hereafter referred to as succinate), which greatly increases succinate in the cytosol 110	
and mitochondrial matrix. Succinate enhanced LPS-induced IL-1β mRNA and pro-IL-111	
	 4	
1β protein with an accompanying boost in HIF-1α protein levels (Figure 1A-C), as 112	
previously shown (Tannahill et al., 2013). Succinate also boosted LPS-induced 113	
glycolysis (Supplementary Figure 2A). Importantly, this synergistic effect of 114	
exogenous succinate and LPS did not occur for another pro-inflammatory cytokine, 115	
tumor necrosis factor-α (TNF-α) (Figure 1D, E) demonstrating the specificity of this 116	
response. Succinate alone had no effect on cytokine production, nor did it affect 117	
LPS-induced NFκB activation either on its own (Figure 1F, left-hand side) or in 118	
combination with LPS (right-hand side), as measured by p65 phosphorylation (top 119	
panel) or IκB degradation (third panel). Conversely, succinate inhibited the induction 120	
of the anti-inflammatory cytokines IL-1RA (Figure 1G) and IL-10 (Figure 1H) in 121	
response to LPS. The effect of succinate on IL-10 was rapid, being evident from 1 h, 122	
and sustained for both mRNA (Figure 1H) and protein (Figure 1I) induction, and was 123	
concentration-dependent (Figure 1J). While two other Krebs cycle metabolites, α-124	
ketoglutarate (α-KG) and fumarate, increased LPS-induced IL-1β message their 125	
effects on LPS-induced pro-IL-1β were far less robust than for succinate 126	
(Supplementary Figure 1A, B), and only succinate decreased LPS-induced IL-10 127	
production (Supplementary Figure 1C, left-hand side). Furthermore, fumarate also 128	
boosted LPS-induced TNF-α suggesting its pro-inflammatory effects are 129	
mechanistically distinct from succinate (Supplementary Figure 1C, right-hand side). 130	
Moreover, diethyl butyl malonate (DEBM), an inhibitor of the mitochondrial succinate 131	
transporter, which causes endogenous succinate to accumulate, boosted LPS-132	
induced IL-1β and limited IL-10 with no effect on TNF-α (Supplementary Figure 1D-133	
F). These findings suggest that succinate acts within the cell to enhance and sustain 134	
endogenous pro-inflammatory gene expression, while at the same time inhibiting 135	
anti-inflammatory gene expression.  136	
 137	
Mitochondrial succinate oxidation alters the expression of pro- and anti-138	
inflammatory genes 139	
 140	
To examine how succinate within macrophages might be having its opposing effects 141	
on pro- and anti-inflammatory pathways, we investigated two of the ways in which 142	
succinate could act within the cell: either by enhancing HIF-1α activation by inhibiting 143	
prolyl hydroxylase (PHD) function or as a result of oxidation by mitochondrial 144	
succinate dehydrogenase (SDH). Succinate was found to robustly boost LPS-145	
induced HIF-1α protein levels, an effect that was not observed by any other 146	
metabolite tested (Supplementary Figure 2D). Moreover, the HIF-1α activator 147	
dimethyloxalylglycine (DMOG) mimicked the effect of succinate on IL-1β 148	
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(Supplementary Figure 2F, right-hand side, G). Succinate did not alter the expression 149	
of cMyc, another transcription factor with a known role in the regulation of 150	
macrophage function (Pello et al., 2012), nor the expression of its downstream target 151	
CD71 (Supplementary Figure 2H-J). We therefore conclude that succinate’s pro-152	
inflammatory effects require HIF-1α stabilization.    153	
We also tested the cell permeable molecule dimethyl malonate (DMM), which is 154	
rapidly hydrolysed within the cell to generate malonate, a potent competitive inhibitor 155	
of succinate oxidation by SDH (Dervartanian and Veeger, 1964). DMM led to an 156	
increase in succinate in the cytosol, presumably by impairing the oxidation of 157	
succinate to fumarate, and also boosted LPS-induced succinate accumulation 158	
(Figure 2A). Importantly, succinate and malonate were the only two metabolites 159	
significantly altered by the addition of DMM in the presence or absence of LPS 160	
demonstrating specificity (Supplementary Figure 3A-J). DMM should inhibit effects of 161	
succinate that act through SDH in the mitochondria, but enhance succinate action 162	
through PHD in the cytosol (as a result of the succinate boost evident by this agent). 163	
Intriguingly, in direct opposition to succinate, DMM abrogated LPS-induced IL-1β 164	
mRNA (Figure 2B), pro-IL-1β protein and HIF-1α (Figure 2C, compare lane 5 to lane 165	
7), while leaving TNF-α unaffected (Figure 2D, E). At earlier time points it appeared 166	
that DMM limited LPS-induced cMyc (Supplementary Figure 2H) however this was 167	
not significant and at later time points, when DMM alters IL-1β, DMM had no effect 168	
on cMyc (Supplementary Figure 2I, J). Again in opposition to succinate, DMM 169	
boosted LPS-induced IL-1RA (Figure 2F) and IL-10 expression and production 170	
(Figure 2G, H). These data indicate that, in addition to direct effects on PHDs in the 171	
cytosol, the oxidation of succinate by mitochondria is central to the pro-inflammatory 172	
response of LPS-activated macrophages.  173	
As IL-10 and IL-1β were reciprocally regulated by DMM we examined whether IL-10 174	
itself may be responsible for the regulation of IL-1β by this compound. This was not 175	
the case as DMM still inhibited LPS-induced pro-IL-1β in the presence of an IL-10 176	
receptor blocking antibody (Supplementary Figure 2K). 177	
To further examine a role for SDH activity in the pro-inflammatory effects of succinate 178	
we next employed macrophages from mice lacking the B subunit of SDH. The B 179	
subunit is required for succinate to reduce ubiquinone (Guzy et al., 2008) and its 180	
absence will therefore block succinate oxidation. LPS-induced pro-IL-1β and HIF-1α 181	
were decreased in SDHB-deficient BMDMs (Figure 2I, upper and middle panels 182	
respectively, compare lane 2 to lane 4) while TNF-α was unchanged (Figure 2J).  183	
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 184	
To gain further insight into how the manipulation of mitochondrial succinate oxidation 185	
might alter the phenotype of macrophages we next determined the effects of 186	
succinate and DMM on the macrophage genome by performing RNA sequencing 187	
analysis. This revealed whole sets of LPS-induced genes that were altered by DMM 188	
or succinate pretreatment (Figure 3, Supplementary Figure 3K-M and Supplementary 189	
Tables 1-3). The gene expression values in different samples were modeled with a 190	
generalized linear model (details in Methods). Of particular relevance is that many 191	
genes that were down-regulated by DMM were reciprocally up-regulated by 192	
succinate and vice versa (Supplementary Figure 3M), further suggesting that the 193	
metabolism of succinate by SDH is crucial for its pro-inflammatory action. These 194	
gene sets were related to immune response pathways including interferon (IFN) 195	
signaling, the cellular response to hypoxia, fatty acid metabolism, glycolytic 196	
processes and positive and negative regulation of homeostasis (illustrated in Figure 197	
3B). A direct comparison of LPS stimulation under pretreatment with DMM or 198	
succinate confirmed this, as several biological pathways related to homeostasis, 199	
metabolism and inflammation were affected (Figure 3C) even under this stricter 200	
comparison. Most importantly, DMM suppressed expression of genes associated 201	
with inflammation (including those encoding IL-1β, HIF-1α-dependent genes and 202	
genes involved in fatty acid synthesis) whilst boosting anti-inflammatory gene 203	
expression (such as the genes encoding IL-1RA and several type I IFN-inducible 204	
genes) (Figure 3B, blue histobars). Succinate had the opposite effect, boosting pro-205	
inflammatory gene expression whilst decreasing anti-inflammatory gene expression 206	
(Figure 3B, red histobars). The reciprocal regulation of IL-1β and IL-1RA (both 207	
indicated with an arrow) is especially noteworthy. Type I IFNs are also of interest as 208	
they inhibit LPS-induced pro-IL-1β production and boost IL-10 in BMDMs (Guarda et 209	
al., 2011) providing further mechanistic evidence for the regulation of IL-10, and 210	
indeed of IL-1β, by these agents. As expected, RNA sequencing revealed that 211	
succinate induced, while DMM limited, HIF-1α activity. These findings suggest that 212	
HIF-1α is an important part of the mechanism by which succinate and DMM regulate 213	
IL-1β, and confirm that the extent of succinate oxidation by mitochondrial SDH 214	
controls LPS-induced gene expression. When active, SDH boosts inflammatory gene 215	
expression and when inhibited an anti-inflammatory phenotype ensues. 216	
Taken together these results indicate that SDH is a critical regulator of the 217	
macrophage phenotype. Inhibiting SDH causes succinate to accumulate but 218	
importantly prevents the induction of a range of pro-inflammatory factors typified by 219	
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IL-1β, whilst enhancing a range of anti-inflammatory factors, typified by IL-1RA and 220	
IL-10. Increased oxidation of succinate by SDH in mitochondria is therefore required 221	
for the induction of pro-inflammatory genes, whilst simultaneously limiting the 222	
induction of anti-inflammatory ones.  223	
 224	
Inhibition of succinate dehydrogenase in vivo is anti-inflammatory 225	
 226	
To examine if SDH activity was also involved in the pro-inflammatory response in 227	
vivo we next investigated the effect of DMM on LPS action in mice. DMM was 228	
effective in an LPS-induced sepsis model, where it decreased serum levels of IL-1β 229	
(Figure 4A) and boosted IL-10 (Figure 4B), but had no significant effect on TNF-α 230	
(Figure 4C). DMM reduced IL-1β (Figure 4D, E) and PHD3 expression (Figure 4F) in 231	
the spleen. SDH activity is therefore critical for determining the inflammatory 232	
phenotype, both in vitro and in vivo.  233	
 234	
Glycolytic ATP production facilitates an increase in mitochondrial membrane 235	
potential that is required for the pro-inflammatory effects of LPS 236	
 237	
To further explore the mechanism by which SDH might affect the macrophage 238	
phenotype, we next considered how SDH activity interacts with other metabolic 239	
changes occurring in LPS-activated macrophages. A hallmark of the pro-240	
inflammatory phenotype of macrophages is their switch away from ATP production 241	
by oxidative phosphorylation to glycolytic metabolism (O'Neill and Pearce, 2016; 242	
Tannahill et al., 2013). Previous work showed that inhibiting glycolysis with 2-243	
deoxyglucose (2DG) prevented activation of HIF-1α and induction of IL-1β in LPS-244	
treated macrophages yet had no effect on TNF-α production (Tannahill et al., 2013) 245	
(Supplementary Figure 4A-D). These data suggested that the enhanced glycolytic 246	
ATP production upon activation may act in combination with the stimulation of SDH 247	
to sustain the pro-inflammatory phenotype. We hypothesized that the increased ATP 248	
generated by glycolysis in the cytosol would significantly decrease the requirement 249	
for mitochondrial oxidative phosphorylation to supply ATP to the cell. Such a shift 250	
would decrease resting oxygen consumption by the mitochondrial respiratory chain, 251	
as has been shown previously (Tannahill et al., 2013). Here we demonstrate that 252	
glycolysis is boosted by LPS (Figure 5A) and oxygen consumption is decreased 253	
(Figure 5B), yet not abrogated, by LPS (Figure 5E). LPS decreased the ATP/ADP 254	
ratio consistent with a shift from ATP synthesis by oxidative phosphorylation 255	
to ATP synthesis by glycolysis (Figure 5D). Importantly, addition of oligomycin, which 256	
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will abolish any contribution to ATP synthesis by the ETC, to control cells 257	
dramatically decreased respiration yet had no affect the ATP/ADP ratio in LPS-258	
treated cells (Figure 5D). Taken together these data indicate that following LPS 259	
treatment cells were not making ATP by mitochondrial oxidative phosphorylation. It is 260	
interesting to note that inhibition of the ATP synthase with oligomycin decreased 261	
LPS-induced IL-1β suggesting that some level of ATP synthesis within the 262	
mitochondrial matrix may be necessary for the generation of a pro-inflammatory 263	
response (Supplementary Figure 5). The NAD+/NADH ratio also decreased with LPS 264	
treatment (Figure 5C) consistent with a decrease in mitochondrial NADH oxidation 265	
and complex I forward activity. 266	
 267	
Cells that are making ATP by glycolysis and not by mitochondrial oxidative 268	
phosphorylation, as in the case of LPS activation, are expected to have a higher 269	
mitochondrial membrane potential (ΔΨm). This is because the ΔΨm, which is 270	
generated by proton pumping through complexes I, III and IV across the 271	
mitochondrial inner membrane, is no longer being used by the ATP synthase to 272	
make ATP. We found that LPS increased ΔΨm as measured by potential-sensitive 273	
TMRM fluorescence, by flow cytometry and by confocal microscopy (Figure 5F-H). 274	
The percentage of cells with an elevated ΔΨm increased from 6.18% to 47.1% in 275	
response to LPS and this was decreased to 26.1% when glycolysis was inhibited 276	
with 2DG (Figure 5I). This suggests that the increased ATP supply by glycolysis and 277	
the consequential decrease in requirement for mitochondrial ATP production leads to 278	
an increase in the ΔΨm that is important for LPS signaling. To determine if there was 279	
indeed a requirement for increased membrane potential in LPS signaling we next 280	
explored the effect of the uncoupler carbonylcyanide m-chlorophenylhydrazone 281	
(CCCP) on LPS-activated macrophages. As expected, addition of CCCP led to a 282	
decrease in ΔΨm (Figure 5H) and a boost in respiration, which reached its maximum 283	
effect on these variables at 5-10 µM CCCP indicating complete uncoupling  284	
(Supplementary Figure 4G). Concentrations of CCCP sufficient to uncouple 285	
mitochondria also decreased LPS-induced IL-1β expression (Figure 5J and 286	
Supplementary Figure 4H), and pro-IL-1β levels (Figure 5K, compare lane 7 to lanes 287	
8, 9, 10), but only affected TNF-α at higher concentrations where cellular viability was 288	
impaired (Supplementary Figure 4F, J). Dissipation of the mitochondrial membrane 289	
potential with CCCP or 2DG also impaired LPS-induced IL-10 production (Figure 5M 290	
and N, respectively) suggesting that coupled mitochondria are required for the 291	
production of this anti-inflammatory cytokine. Importantly, the lack of effect by both 292	
CCCP and 2DG on TNF-α (Figure 5L and Supplementary Figure 4D, respectively), 293	
	 9	
demonstrates that this cytokine is regulated differently than IL-1β or IL-10, most likely 294	
by a mitochondria-independent mechanism. Together these data suggest that the 295	
shift from oxidative phosphorylation to glycolysis and the consequent elevation in 296	
ΔΨm, in conjunction with the increased succinate, together provide a pro-297	
inflammatory signal.  298	
 299	
Increased membrane potential and succinate oxidation induce the generation 300	
of mitochondrial ROS that drives IL-1β  301	
 302	
As mitochondrial ROS production is greatly enhanced by both an increase in ΔΨm 303	
and an increase in SDH activity (Chouchani et al., 2016) we next examined whether 304	
ROS could act as a redox signal emanating from mitochondria to drive IL-1β 305	
production. Addition of LPS led to an increase in ROS as measured by both MitoSOX 306	
and CellROX (Supplementary Figure 6A and Figure 6A). DMM limited LPS-induced 307	
ROS (Figure 6A and Supplementary Figure 6D) while succinate boosted ROS 308	
production (Figure 6C and Supplementary Figure 6B). This ROS signal led to 309	
increased IL-1β expression as evidenced by the use of a variety of ROS scavengers. 310	
The mitochondria-targeted antioxidants MitoQ (Kelso et al., 2001) (Figure 6B, left-311	
hand side; compare lanes 3 and 4 to lanes 7 and 8) and MitoTEMPO (Figure 6B, 312	
right-hand side; compare lanes 3 and 4 to lanes 7 and 8, and 11 and 12) and the 313	
thiol reductant N-acetylcysteine (Supplementary Figure 6C; compare lanes 3 and 4 314	
to lanes 7 and 8, and 11 and 12), all inhibited the effect of succinate on LPS-induced 315	
pro-IL-1β and HIF-1α suggesting that this ROS signal was critical for IL-1β 316	
production in response to succinate. In addition, LPS-induced ROS production was 317	
prevented by dissipating the mitochondrial membrane potential with CCCP (Figure 318	
6D and Supplementary Figure 6E). Together these data suggest that increased 319	
succinate oxidation and an elevation of the mitochondrial membrane potential are 320	
both required to generate a pro-inflammatory mitochondrial ROS signal. 321	
 322	
The complex I inhibitor rotenone significantly decreased LPS-induced ROS (Figure 323	
6E and Supplementary Figure 6F) while also decreasing LPS-induced IL-1β mRNA 324	
expression (Figure 6F) and pro-IL-1β (Figure 6G, compare lane 7 to lanes 8, 9 and 325	
10) yet had no effect on TNF-α (Figure 6H), supporting a role for complex I activity in 326	
ROS production in this system. To further investigate the role of mitochondrial ROS 327	
in LPS-activated macrophages we used BMDMs from mice expressing an alternative 328	
oxidase (AOX) from Ciona intestinalis (El-Khoury et al., 2014) AOX provides a 329	
pathway to oxidise excess electrons that build up in the ubiquinone (CoQ) pool, for 330	
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example as a result of succinate accumulation, that can contribute to mitochondrial 331	
ROS production. AOX was confirmed to be present in BMDMs from these mice 332	
(Figure 6I) (Fernandez-Ayala et al., 2009). AOX-expression in BMDMs impaired the 333	
boost in ROS production following LPS treatment (Figure 6J and Supplementary 334	
Figure 4K) and strongly impaired the boost in LPS-induced IL-1β and HIF-1α with 335	
succinate (Figure 6M, compare lanes 3 and 4 to lanes 7 and 8). There was no 336	
difference in the observed LPS-induced boost in membrane potential between wild-337	
type and AOX-expressing BMDMs (Figure 4K, L). Crucially, AOX expression 338	
increased the survival of mice injected with LPS. There was 50% mortality in wild-339	
type mice while in AOX-expressing mice survival remained above 80% (Figure 6N). 340	
These data suggest that limiting ROS production either pharmacologically or using 341	
genetic approaches limits IL-1β levels and is protective against LPS lethality, 342	




Alterations in mitochondrial metabolism following LPS treatment of macrophages are 347	
now understood to be vital for an appropriate immune response (Mills and O'Neill, 348	
2016). Studies dating back to the 1970s demonstrated that LPS attenuates 349	
macrophage respiration by inhibiting complexes II and III (Kato, 1972) and slowing 350	
state III respiration (McGivney and Bradley, 1979). LPS also alters the Krebs cycle, 351	
effectively breaking it at two points: after citrate and after succinate (Jha et al., 2015). 352	
Furthermore, previous studies have shown that LPS increases mitochondrial ROS 353	
production (West et al., 2011) as an important response for bacterial killing in 354	
macrophages, but the mechanism was obscure. Our study shows that mitochondrial 355	
ROS generation following the oxidation of succinate is central to determining the 356	
inflammatory phenotype of macrophages.  357	
 358	
This study provides a model that explains the many disparate aspects of the 359	
metabolic changes that occur upon activation of macrophages with LPS. Together 360	
these findings suggest that an important consequence of the shift to glycolytic ATP 361	
production upon activation of macrophages is the release of mitochondria from their 362	
requirement to produce ATP by oxidative phosphorylation, thereby enabling the 363	
mitochondrial membrane potential to increase. This is coupled with the remodeling of 364	
metabolism to funnel metabolites to succinate, the oxidation of which we have 365	
demonstrated is critical in the regulation of the inflammatory state of macrophages. 366	
We demonstrate that succinate oxidation and a high mitochondrial membrane 367	
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potential generate a redox signal that can alter HIF-1α activity. This is in agreement 368	
with a recent study performed in keratinocytes demonstrating a critical role for ROS 369	
derived from the ETC in HIF-1α stabilization (Hamanaka et al., 2016). Crucially we 370	
report that these events alter the expression levels of a range of pro and anti-371	
inflammatory genes. The inflammatory phenotype of the macrophage, as indicated 372	
by increased inflammatory gene expression and reciprocally decreased anti-373	
inflammatory gene expression, is governed by succinate oxidation by SDH. We 374	
demonstrate that ROS drive expression of cytokines such as IL-1β via HIF-1α. 375	
Precisely how succinate inhibits anti-inflammatory gene expression is under 376	
investigation. This may involve succinate-induced regulation of other members of the 377	
α-KG-dependent dioxygenase family such as those involved in epigenetic changes 378	
occurring in macrophages (Yang and Pollard, 2013). We are currently investigating 379	
this possibility. From our data it is clear, nevertheless, that SDH is a key arbiter for 380	
the inflammatory response in macrophages. Furthermore, our observation that TNF-381	
α is not controlled by SDH points to specificity in the role of the mitochondria in the 382	
regulation of cytokine production.  In a recent study by Sancho and colleagues, live 383	
bacteria were shown to alter the assembly of the ETC via the sensing of bacterial 384	
RNA, further emphasizing the importance of mitochondrial alterations in innate 385	
immunity (Garaude et al., 2016). 386	
 387	
It was interesting to note that dimethyl fumarate, a cell permeable fumarate ester, 388	
which has recently been approved as the front-line drug for the treatment of 389	
relapsing-remitting multiple sclerosis (Miljkovic et al., 2015), boosted both LPS-390	
induced IL-1β expression and TNF-α production. These effects were somewhat 391	
surprising, as dimethyl fumarate has been suggested to exert its beneficial effects in 392	
disease largely by decreasing neuroinflammation. It has been shown to decrease 393	
ROS production in macrophages (Haas et al., 2015), most likely as a consequence 394	
of its effects on anti-oxidants such as heme oxygenase-1, superoxide dismutase-2 395	
and nuclear factor erythroid 2-related factor 2 (Nrf2), and to decrease IL-1β mRNA 396	
expression in microglial cells (Wilms et al., 2010). However, it is known that fumarate 397	
can stabilize HIF-1α and this is likely the mechanism by which is inducing IL-1β 398	
(Isaacs et al., 2005). Similarly, there may be an as yet unknown factor by which 399	
fumarate boosts TNF-α production or this may be a result of epigenetic alterations of 400	
the TNF-α gene, which have been reported elsewhere (Sullivan et al., 2007; Xiao et 401	
al., 2012).  402	
 403	
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There are a number of possible sources for the ROS signal emanating from 404	
mitochondria in response to succinate oxidation and an elevated membrane 405	
potential, including from complex I and complex III (Chandel et al., 2000). We favour 406	
the hypothesis that the ROS signal is generated by reverse electron transport (RET) 407	
at complex I of the ETC. Complex I can produce large amounts of ROS by the 408	
precisely regulated process of RET when the CoQ pool is highly reduced and the 409	
mitochondrial membrane potential is high, together providing the thermodynamic 410	
driving force to push electrons in reverse to the ROS-producing site within complex I 411	
(Chance and Hollunger, 1961). Importantly, succinate has long been known to drive 412	
RET and recently has been shown to generate ROS production by RET during 413	
ischemia-reperfusion (I/R) injury (Chouchani et al., 2014). The data we present in this 414	
study indicate that the ROS signal is sensitive to uncoupling with CCCP, prevention 415	
of succinate oxidation by DMM, oxidation of the CoQ pool by expression of AOX 416	
(Perales-Clemente et al., 2008) and inhibition of complex I with rotenone, all of which 417	
are consistent with RET at complex I as the source of the pro-inflammatory ROS 418	
signal in LPS-activated macrophages. The decrease in LPS-induced ROS with the 419	
complex I inhibitor rotenone is particularly intriguing as this inhibitor only lowers ROS 420	
by complex I if RET is occurring (Votyakova and Reynolds, 2001), and otherwise 421	
induces ROS production (Barrientos and Moraes, 1999). The role of RET in 422	
metabolic signaling has been implicated in a number of recent studies, such as I/R 423	
injury (Chouchani et al., 2014), mitochondrial ROS production during ageing in 424	
Drosophila, (Scialo et al., 2016) and in hypoxia sensing in the carotid body 425	
(Fernandez-Aguera et al., 2015). Furthermore, previous reports demonstrated that 426	
metformin, which inhibits complex I, decreases IL-1β in response to LPS (Kelly et al., 427	
2015). Also of interest is the recent identification of TLR4 as a driver of ROS and 428	
subsequent systemic inflammation in mice deficient in the complex I subunit Ndufs4 429	
(Jin et al., 2014), further emphasizing modulation of complex I by TLR4. While further 430	
work is required to assess the source of mitochondrial ROS during macrophage 431	
activation, we feel that RET at complex I is a strong candidate.  432	
 433	
This central role for mitochondria in immune signaling and the innate immune 434	
response fits with the function of this organelle in many other aspects of cell death 435	
and signaling. Indeed, the endosymbiotic origins of mitochondria may not only reflect 436	
the requirement for eukaryotes to evolve to respire oxidatively but these organelles 437	
might also have evolved to serve as signaling hubs, which can influence the 438	




Finally, the finding that succinate oxidation is an important regulator of inflammatory 442	
signaling opens up a number of new therapeutic opportunities. For example, DMM 443	
may be useful in the treatment of inflammatory diseases in which IL-1β has been 444	
linked to pathogenesis (Dinarello, 2011). Promisingly, inhibition of SDH with DMM 445	
has shown efficacy here in a mouse model of acute LPS-induced sepsis and 446	
previously in mouse models of Escherichia coli infection (Garaude et al., 2016) and 447	
I/R injury (Chouchani et al., 2014). Treatment with DMM or derivatives may therefore 448	
improve disease outcome by restoring the balance between IL-1β and IL-1RA, or 449	
indeed by increasing IL-10 production, which can both decrease IL-1β and enhance 450	
IL-1RA levels (Cassatella et al., 1994) and suppress inflammation more generally 451	
(Couper et al., 2008). The shift in macrophages away from inflammatory gene 452	
expression towards anti-inflammatory gene expression within an inflammatory 453	
environment (such as in our LPS model) is especially noteworthy since such an 454	
environment will prevail in inflammatory diseases where inhibitors of SDH might 455	
prove especially useful. 456	
 457	
Contact for reagent and resource sharing 458	
 459	
For further information, queries may be directed to the corresponding authors Luke 460	
A. O’Neill (laoneill@tcd.ie) and Michael P. Murphy (mpm@mrc-mbu.cam.ac.uk). 461	
Requests for reagents will be fulfilled by the lead contact.  462	
 463	
Experimental model and subject details 464	
 465	
Mouse strains  466	
 467	
Wild type C57Bl/6 mice were from Harlan U.K. and Harlan Netherlands. Animals 468	
(female; 8-12 weeks) were maintained under specific pathogen-free conditions in line 469	
with Irish and European Union regulations. Experiments were approved by local 470	
ethical review (Health Products Regulatory Authority) and were carried out under the 471	
authority of Ireland’s project license. C57Bl/6 mice carrying a single copy of Ciona 472	
intestinalis AOX gene in the Rosa26 locus were generated by T. Braun, H. T. Jacobs 473	
and M. Szibor (full details to be published elsewhere). Animals (females; 22-37 474	
weeks) were maintained under specific pathogen-free conditions. LPS experiments 475	
in AOX-expressing mice were carried out by Luria Scientific Industries under the 476	
IACUC Assurance number A7433J45. Legs from AOX-expressing mice were 477	
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supplied by M. Szibor, H. T. Jacobs (both University of Helsinki, Finland) and M. P. 478	
Murphy (University of Cambridge, UK). Legs from SDHB-deficient mice (males and 479	
females; 8-22 weeks; maintained under specific pathogen-free conditions) were a gift 480	
from E. Gottlieb (University of Glasgow, UK).  481	
 482	
Bone marrow-derived macrophage (BMDM) generation 483	
 484	
Mice were euthanized in a CO2 chamber and death was confirmed by cervical 485	
dislocation. Bone marrow cells were extracted from the leg bones and differentiated 486	
in DMEM (containing 10% foetal calf serum, 1% penicillin streptomycin and 20% 487	
L929 supernatant) for 6 days, at which time they were counted and replated for 488	
experiments. Unless stated, 0.5x106 BMDMs per millilitre were used in in vitro 489	
experiments. 490	
 491	
Endotoxin-induced model of sepsis 492	
 493	
Female C57/Bl6 mice (aged 7 – 9 weeks, weighing 13 – 20 g) were randomly 494	
assigned to experimental groups (5 mice per group). Mice were treated i.p. ± 495	
dimethyl malonate (160 mg/kg) or PBS for 3 h prior to stimulation with LPS (15 496	
mg/kg) i.p. for 2 h. Mice were euthanized in a CO2 chamber and peritoneal cells, 497	
spleens and whole blood samples were harvested. AOX-expressing mice were 498	






Total RNA was isolated using the RNeasy Plus Mini kit (Qiagen) and quantified using 505	
a Nanodrop 2000 UV-visible spectrophotometer. cDNA was prepared using 20–100 506	
ng/µl total RNA by a reverse transcription-polymerase chain reaction (RT-PCR) using 507	
a high capacity cDNA reverse transcription kit (Applied Biosystems), according to the 508	
manufacturer’s instructions. Real-time quantitative PCR (qPCR) was performed on 509	
cDNA using SYBR Green probes specific for IL-1β, IL-10, TNF-α, IL-1RA and Rps18, 510	
or Taqman probes specific for HIF-1α, PHD3 and Rps18. qPCR was performed on a 511	
7900 HT Fast Real-Time PCR System (Applied Biosystems) using Kapa fast master 512	
mix high ROX (Kapa Biosystems, for SYBR probes) or 2X PCR fast master mix 513	
(Applied Biosystems, for Taqman probes). The SYBR primer pair sequences were as 514	
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follows: Il1b, FW 5’-TGGCAACTGTTCCTG-3’, RV 5’-GGAAGCAGCCCTTCATCTTT-515	
3’; Il10, FW 5’-AGGCGCTGTCATCGATTT-3’, RV 5’-516	
CACCTTGGTCTTGGAGCTTAT-3’; Tnfa, FW 5’-GCCTCTTCTCATTCCTGCTT-3’, 517	
RV 5’-TGGGAACTTCTCATCCCTTTG-3’; Rps18, FW 5’-518	
GGATGTGAAGGATGGGAAGT-3’, RV 5’-CCCTCTATGGGCTCGAATTT-3’; Il-1ra, 519	
FW 5’-TTGTGCCAAGTCTGGAGATG-3’, RV 5’-CTCAGAGCGGATGAAGGTAAAG-520	
3’; Phd3, FW 5’-TGCTGAAGAAAGGGCAGAAG-3’; RV 5’-521	
GCACACCACAGTCAGTCTTTA -3’; cMyc, FW 5'-CCACCAGCAGCGACTCTG-3', 522	
RV 5'-GAGATGAGCCCGACTCCG-3'; CD71, FW 5'-523	
AAGTGACGTAGATCCAGAGGG-3', RV 5'-GACAATGGTTCCCCACCAAA-3'. Fold 524	
changes in expression were calculated by the Delta Delta Ct method using mouse 525	
Rps18 as an endogenous control for mRNA expression. All fold changes are 526	




Protein samples from cultured cells were prepared by direct lysis of cells in 5X 531	
Laemmli sample buffer, followed by heating at 95°C for 5 min. For spleen samples, 532	
30 mg of spleen was homogenized in RIPA buffer using the Qiagen TissueLyserII 533	
system. The resulting homogenate was centrifuged at 14000 rpm for 10 min at 4°C, 534	
and supernatants were used for SDS-PAGE. Protein samples were resolved on 8% 535	
or 12% SDS-PAGE gels and were then transferred onto polyvinylidene difluoride 536	
(PVDF) membrane using either a wet or semi-dry transfer system. Membranes were 537	
blocked in 5% (w/v) dried milk in Tris-buffered saline-Tween (TBST) for at least one 538	
hour at room temperature. Membranes were incubated with primary antibody, 539	
followed by the appropriate horseradish peroxidase-conjugated secondary antibody. 540	
They were developed using LumiGLO enhanced chemiluminescent (ECL) substrate 541	
(Cell Signalling). Bands were visualized using the GelDoc system (Biorad). 542	
 543	
Enzyme-linked immunosorbent assay 544	
 545	
Cytokine concentrations in cell supernatants were measured using enzyme-linked 546	
immunosorbent assay (ELISA) Duoset kits for mouse IL-10 and TNF-α, according to 547	
the manufacturer’s instructions. Cytokine concentrations in serum samples isolated 548	
from whole blood were measured using Quantikine ELISA kits for mouse IL-1β, IL-10 549	
and TNF-α. Duoset and Quantikine kits were from R&D Systems. Optical density 550	
values were measured at a wavelength of 450 nm, using a FLUOstar Optima plate 551	
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reader (BMG Labtech). Concentrations were calculated using a 4-parameter fit 552	
curve. 553	
 554	
Flow cytometric analysis of reactive oxygen species 555	
 556	
BMDMs were seeded at 0.5x106 cells/ml. One well was seeded for each of the 557	
following controls: unstained cells, single-stained cells and dead cells. For cellular 558	
reactive oxygen species (ROS) measurements cells were treated and stimulated as 559	
normal. 2 hours prior to staining, 100% EtOH was added to the dead cell control well. 560	
30 minutes prior to the end of the stimulation, CellROX (5 µM) was added directly 561	
into the cell culture medium. Supernatants of cells that were to be stained with Aqua 562	
Live/Dead were removed, and an Aqua Live/Dead dilution (1 ml; 1 in 1000 in PBS) 563	
was added to each well. Cells were incubated in tinfoil at 37°C for 30 min. For 564	
mitoROS measurements MitoSOX (5 µM) and Aqua Live/Dead were each added for 565	
30 min prior to stimulation. The media was then removed and replaced with stimulus-566	
containing media. The supernatant was removed and cells were scraped in PBS (1 567	
ml), before being transferred to polypropylene FACS tubes. Cells were centrifuged at 568	
2000 rpm for 3 min. Cells were washed in PBS and centrifuged two further times, 569	
and were finally resuspended in PBS (500 µl). BMDMs were analyzed using a Dako 570	




BMDMs were plated at 0.5x106 cells/ml in 10 cm non-cell culture-treated dishes (10 575	
ml/dish) and treated as required. NAD+/NADH was assayed using an NAD+/NADH 576	




BMDMs were plated at 0.5x106 cells/ml in white 96-well plates (100 µl/well) and 581	
treated as required. ATP/ADP was assayed using an ATP/ADP quantification 582	




To determine cytotoxicity, cells were plated at 0.5x106 cells/ml in white 24-well plates 587	
(500 µl/well) and treated as required. Cytotoxicity, as determined by LDH release, 588	
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was assayed using CytoTox96 Non-radioactive Cytotoxicity Assay kit (Promega) 589	




Cell culture medium 594	
Cell culture supernatant (50 µl) was centrifuged at maximum speed for 5 min at 4°C. 595	
The supernatant was transferred to a fresh microcentrifuge tube and resuspended in 596	
extraction buffer (750 µl; EB; 50% methanol, 30% acetonitrile, 20% dH2O, 100 ng/ml 597	
HEPES). Samples were agitated for 15 min at 4°C and then centrifuged at maximum 598	
speed for 10 min at 4°C. The resultant supernatant was transferred into autosampler 599	




Cells were washed three times with ice-cold PBS, with all of the PBS being removed 604	
after the last wash. EB was added (1 ml per 1x106 cells). Samples were agitated for 605	
15 min at 4°C. The resultant suspension was transferred to ice-cold microcentrifuge 606	
tubes and centrifuged at maximum speed for 10 min at 4°C. The supernatant was 607	
transferred into autosampler vials and stored at -80°C prior to analysis by LC-MS. 608	
  609	
LC-MS analysis of sample extracts was performed on a QExactive Orbitrap mass 610	
spectrometer coupled to a Dionex UltiMate 3000 Rapid Separation LC system 611	
(Thermo). The liquid chromatography system was fitted with a SeQuant Zic-HILIC 612	
(150 mm × 4.6 mm, 5 µm) with guard column (20 mm × 2.1 mm, 5 µm) from Merck 613	
(Darmstadt, Germany). The mobile phase was composed of 0.1% formic acid in 614	
water (solvent A), and 0.1% formic acid in acetonitrile (solvent B), and the flow rate 615	
set at 300 µL x min-1. The mass spectrometer was operated in full MS and polarity 616	
switching mode. Samples were randomized in order to avoid machine drift, and 617	
blinded to the operator. The acquired spectra were analyzed using XCalibur Qual 618	
Browser and XCalibur Quan Browser software (Thermo Scientific) by referencing to 619	
an internal library of compounds. 620	
 621	
Oxygen consumption and lactate production analysis 622	
 623	
Cells were plated at 0.2x106 cells/well of a 24-well Seahorse plate with one well per 624	
row of the culture plate containing only supplemented media without cells, as a 625	
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negative control. Cells were treated and stimulated as normal. A utility plate 626	
containing calibrant solution (1 ml/well) together with the plates containing the 627	
injector ports and probes was placed in a CO2-free incubator at 37°C overnight. The 628	
following day media was removed from cells and replaced with glucose-629	
supplemented XF assay buffer (500 µl/well) and the cell culture plate was placed in a 630	
CO2-free incubator for at least 0.5 h. Inhibitors (Oligomycin, carbonyl cyanide-4-631	
(trifluoromethoxy)phenylhydrazone (FCCP), 2DG, Rotenone; 70 µl) were added to 632	
the appropriate port of the injector plate. This plate together with the utility plate was 633	
run on the Seahorse for calibration. Once complete, the utility plate was replaced 634	
with the cell culture plate and run on the Seahorse XF-24.   635	
 636	
Mitochondrial membrane potential 637	
 638	
 Confocal microscopy 639	
Cells were plated at 0.3x106 cells/ml in DMEM containing 10% FCS and 1% P/S in 640	
CELLview cell culture dishes containing four compartments per dish (500 641	
µl/compartment). TMRM cell-permeable fluorescent dye was either added before or 642	
after stimulation depending on the length and nature of treatment. In the case of 643	
LPS-treated cells following stimulation media was removed and replaced with 644	
TMRM-containing media (20 nM) and incubated at 37° in the dark for 30 min. 645	
Oligomycin or CCCP was added after the addition of TMRM for 1 h or 2 min 646	
respectively. Cells were imaged on a Leica SP8 confocal microscope with an 647	
excitation laser of 550 nm and detection set for 560-650 nM using a 40x oil-objective 648	
lens. A number of images were taken for each treatment. 649	
 650	
 Flow cytometry 651	
Cells were plated at 0.5x106 cells/ml in 12-well plates. The following control cell 652	
samples were accounted for: unstained, single-stained TMRM, MitoTracker Green 653	
(MTG) and Aqua Live/Dead stain and 100% dead cells (treated with 100% ethanol 654	
for 1 h). Cells were prepared and treated as normal. TMRM stock was made up in 655	
DMSO (10 mM). MTG and Aqua Live/Dead stain were prepared by the addition of 656	
DMSO (75 µl or 50 µl/vial respectively). Supernatants were removed from all cells 657	
that were to be stained with Aqua Live/Dead (i.e. all samples except single-stained 658	
and unstained controls) and this was replaced with PBS (1 ml) containing Aqua 659	
Live/Dead stain (1 µl) and incubated at 37°C in the dark for 30 min. A mix of PBS 660	
containing MTG (50 nM) and TMRM (20 nM) was made up. Supernatant was 661	
removed from cells to be stained with MTG and TMRM (i.e. all samples except 662	
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single-stained and unstained controls) and this was replaced with PBS containing 663	
MTG and TMRM (1 ml) and incubated at 37°C in the dark for 30 min. Supernatants 664	
were removed and cells were washed with PBS (1 ml). PBS (500 µL) was added per 665	
well and cells were removed from the plate surface using a cell scraper and 666	
transferred to polypropylene FACS tubes. Cells were then analyzed using a 667	
LSRFortessa flow cytometer, and data were analyzed using FlowJo software. 668	
 669	
In vitro deletion of SDHB 670	
 671	
BMDMs from mice carrying a SDHB fl/fl allele were utilized. Ablation of SDHB was 672	
achieved by adding 4-hydroxytamoxifen (600 nM) on day 4 of macrophage 673	
differentiation and again for a further 24 h when cells were replated on day 6. Ethanol 674	
was used as a vehicle control for the 4-hydroxytamoxifen treatment.  675	
 676	
Quantification and statistical analysis 677	
 678	
Statistical analysis 679	
Comparisons between two groups were calculated using one- or two-tailed 680	
student’s t-tests, using Graphpad Prism software. Data are reported as mean ± 681	
standard error of the mean (S.E.M.). Statistical values, including number of 682	
replicates (n), can be found in the figure legends. *p < 0.05, **p < 0.01, ***p < 683	
0.001. For in vitro experiments, n = number of separate experiments. For in vivo 684	




Total RNA was isolated using the RNeasy Plus Mini kit (Qiagen) and quantified 689	
using a Nanodrop 2000 UV-visible spectrophotometer. cDNA libraries were 690	
generated using the Smart-seq2 protocol modified for 50 ng of total RNA input and 691	
sequenced on a MiSeq (Illumina, San Diego, CA) per manufacturer’s instructions. 692	
Sequences obtained from the RNASeq pipeline were aligned against the Mus 693	
musculus genome using TopHat (Trapnell et al., 2009) + Bowtie (Langmead et al., 694	
2009). HTSeq-count (Anders et al., 2015) was used to count the transcripts 695	
associated with each gene, and a counts matrix containing the number of counts for 696	
each gene across different samples and stimulations was obtained. The counts 697	
were normalized using the TMM method (DOI: 10.1186/gb-2010-11-3-r25). To 698	
analyze differential expression across different stimulations, the counts matrix was 699	
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fitted with a generalized linear model, using the edgeR package. A nested 700	
interaction model involving LPS stimulation and stimulation with DMM or succinate 701	
as the two factors was used to analyze the gene expression. Three comparisons 702	
were made using this model to explore in detail the effects of DMM and succinate 703	
on LPS-activated macrophages - 704	
1. Differential gene expression under stimulation with LPS alone in the base case 705	
was compared to LPS stimulation when the samples were pretreated with DMM or 706	
succinate, and the strength and direction of regulation of expression by these two 707	
compounds was compared to the base case (Figure 3A). A list of genes which 708	
showed statistically significant regulation in opposite directions in both the base 709	
case and with pretreatment (e.g. genes found to have higher expression when 710	
stimulated with succinate + LPS compared with LPS alone, and lower expression 711	
with DMM + LPS compared with LPS alone) was obtained - and analyzed for 712	
biological pathway enrichment in the GO and Kegg databases (Figure 3B). 713	
2. A direct comparison was made between LPS-activated macrophages pretreated 714	
with succinate and LPS-activated macrophages pretreated with DMM to find very 715	
high confidence pathways that were oppositely regulated under both comparisons 716	
(Figure 3C). 717	
3. Further, samples which were treated with LPS at different time points (4 h or 48 718	
h) were analyzed separately to identify genes which were being expressed 719	
differently at different stages of the LPS stimulation (Supplemental Figure 3K-M).  720	
For all the comparisons, an FDR-adjusted p-value of 0.05 was considered to be the 721	
threshold for statistical significance, where the Benjamini-Hochberg test was used 722	
for multiple testing correction. 723	
 724	




Graphpad Prism was used for statistical analysis and graphing. Tophat and Bowtie 729	
were used to align sequences from the RNASeq pipeline against the Mus musculus 730	
genome. HTSeq-count was used to count the transcripts associated with each gene 731	
in the transcriptomics analysis. Details regarding acquisition of all software can be 732	
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Figure 1. Succinate drives IL-1β  production and limits the production of IL-1RA 779	
and IL-10.  780	
BMDMs were pretreated for 3 h with succinate (Suc; 5 mM; A-I, or 0.2 – 5 mM, J) 781	
before being stimulated with LPS (100 ng/ml) for 48 h (A - C, G, J), or the indicated 782	
times (D – F, H, I). mRNA was extracted from total cell lysates and analyzed by 783	
qPCR for IL-1β (A), TNF-α (D) IL-1RA (G) and IL-10 (H) expression. Whole cell 784	
lysates were analyzed by western blotting for pro-IL-1β, HIF-1α, phospho-p65, total 785	
p65, IκBα and β-actin (B, C, F). Supernatants were analyzed by ELISA for TNF-α (E) 786	
and IL-10 production (I, J). The data in (A, D, E, G - J) represent mean ± S.E.M., 787	
n=3, *p<0.05, **p < 0.01. The blots in (B, C F) are representative of 3 independent 788	
experiments. See also Supplemental Figures 1 and 2. 789	
 790	
Figure 2. Inhibition of succinate dehydrogenase impairs LPS-induced IL-1β  791	
production and boosts IL-1RA and IL-10.  792	
BMDMs were pretreated for 3 h with dimethyl malonate (DMM; 10 mM) prior to 793	
stimulation with LPS (100ng/ml) for 24 h (A), 48 h (B, C, E, G, H), or 4 h (D, F). 794	
SDHB-proficient (SDHBfl/fl EtOH) and SDHB-deficient (SDHBfl/fl Tamox) BMDMs were 795	
untreated (Ctl) or treated with LPS (100 ng/µl) for 24 h (I, J). Lysed cells were 796	
analyzed by liquid chromatography-mass spectrometry (LC-MS) to determine 797	
succinate levels (A). mRNA from total cell lysates was analyzed by qPCR for IL-1β 798	
(B), TNF-α (D), IL-1RA (F) and IL-10 (G) expression. Whole cell lysates were 799	
analyzed by Western blotting for pro-IL-1β, HIF-1α and β-actin (C, I). Supernatants 800	
were analyzed by ELISA for TNF-α (E, J) and IL-10 production (H). The data in (A, B, 801	
D - H) represent mean ± S.E.M., n=3. The data in (J) represent mean ± S.E.M., n=6, 802	
*p < 0.05, **p < 0.01, ***p < 0.001. The blots are representative of 3 (C) or 5 (J) 803	
independent experiments. See also Supplemental Figures 1 and 3. 804	
 805	
 806	
Figure 3. Limiting succinate oxidation induces an anti-inflammatory response. 807	
BMDMs were pretreated with dimethyl malonate (DMM; 10 mM) or succinate (5 mM) 808	
for 3 h before being stimulated with LPS (100 ng/µl) for 4 or 48 h. RNA was isolated 809	
and RNA sequencing was performed. The gene expression in the different 810	
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stimulations and time-points was modeled with a generalized linear model, and fold-811	
changes and FDR-adjusted p-values were calculated. Fig 3(A) shows the distribution 812	
of the fold changes (log2FC) and the FDR – adjusted p-values (log FDR) for the 813	
comparison between LPS-treated samples and control – without and with 814	
pretreatment with succinate and DMM. A large number of genes were found to be 815	
oppositely regulated when pretreated with succinate as compared to when they were 816	
pretreated with DMM. Significant changes are coloured red, while the insignificant 817	
changes are coloured grey. Fig 3(B) shows the difference in fold changes when the 818	
BMDMs were pretreated with either DMM or succinate, as compared to when they 819	
were not. The genes are annotated for the immune pathways they belong to. Fig 820	
3(C) shows the results of functional enrichment of our gene expression analysis in 821	
the Kegg and Reactome pathway databases. The heatmap represents the statistical 822	
significance (FDR-adjusted p-value) of the different pathways found to be enriched in 823	
our analysis, with the darker colours denoting pathways enriched with higher 824	
confidence. See also Supplemental Figure 3 and Supplemental Tables 1 to 6. 825	
 826	
Figure 4. Inhibition of succinate dehydrogenase in vivo is anti-inflammatory. 827	
Mice were injected intraperitoneally (i.p.) with DMM (160 mg/kg) or PBS for 3 h, 828	
followed by PBS or LPS (15 mg/kg) for 2 h. Serum was isolated from whole blood 829	
and IL-1β (A), IL-10 (B) and TNF-α (C) production were measured by ELISA. 830	
Spleens were isolated and IL-1β (D) and PHD3 (F) expression were analyzed by 831	
qPCR and pro-IL-1β and β-actin were measured by Western blotting (E). The data in 832	
(A-D, F) represent mean ± S.E.M., n=5 per group, *p < 0.05, **p < 0.01, ***p < 0.001. 833	
Blots are representative of 1 sample from each treatment group.  834	
 835	
Figure 5. Glycolytic ATP production facilitates an increase in mitochondrial 836	
membrane potential that is required for the pro-inflammatory effects of LPS. 837	
(A – E) BMDMs were stimulated with LPS (100 ng/ml) for 48 h (A, B) or 24 h (C, D). 838	
Oxygen consumption rate (OCR) and proton production rate (PPR) were analyzed as 839	
read-outs for for oxidative phosphorylation and glycolysis, respectively, using the 840	
Seahorse XF-24. The NAD+/NADH ratio in cell lysates was determined using an 841	
NAD+/NADH assay kit (C). The ATP/ADP ratio in cell lysates was determined using 842	
an ATP/ADP assay kit (D). BMDMs were untreated (Ctl) or stimulated with LPS (100 843	
ng/ml) for 24 h before OCR analysis using the Seahorse XF-24 (E). During the 844	
Seahorse run, BMDMs were first injected with oligomycin (Oligo; 10 µM) or vehicle 845	
(EtOH), and OCR was measured for the following 6 h. At this point, rotenone (Rot; 846	
100 nM) and antimycin A (4 µM) were injected to all wells to abolish OCR. (F – I) 847	
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BMDMs were untreated (Ctl), treated with LPS (100 ng/ml) for the indicated times (F, 848	
G) or  pretreated with 2-deoxyglucose (2DG; 1 mM) for 3 h prior to LPS for 24 h (I). 849	
Cells were costained with TMRM (20 nM) and MitoTracker Green (50 nM) for 30 min 850	
and then analyzed by FACS to quantify the membrane potential. The intensity of 851	
TMRM staining reflects the membrane potential. To analyse the membrane potential 852	
by confocal microscopy BMDMs were untreated (Ctl), treated with LPS (100 ng/ml) 853	
for 24 h, oligomycin (Oligo: 5 µM) for 1 h or with carbonylcyanide m-854	
chlorophenylhydrazone (CCCP; 10 µM) for 2 min (H). Cells were stained with TMRM 855	
(20 nM) for 30 min prior to imaging. The intensity of TMRM staining reflects the 856	
membrane potential. (J - M) BMDMs were also pretreated with CCCP (0.5-10 µM; J - 857	
M), or 2DG (1 mM; N) for 3 h before being stimulated with LPS (100 ng/ml) for 4 h (J 858	
- M) or 48 h (N). mRNA was extracted from total cell lysates and analyzed by qPCR 859	
for IL-1β expression (J) and whole cell lysates were analyzed by Western blotting for 860	
pro-IL-1β and β-actin (K). Supernatants were analyzed by ELISA for TNF-α (L) and 861	
IL-10 (M, N) production. The data in (A-D, J - M) represent mean ± S.E.M., n=3, 862	
*p=0.05, **p < 0.01, ***p < 0.001. The data in (F) shows quantification of TMRM high 863	
cells and represents mean ± S.E.M., *p<0.05. The cytometric dot plots in (G, I) are 864	
representative from 3 (G) or 4 (I) separate experiments. Images in (H) are 865	
representative from 5 separate experiments. The blots in (K) are representative of 866	
three independent experiments. The Seahorse OCR data in (E) is representative of 4 867	
independent experiments. See also Supplemental Figure 4 and 5. 868	
 869	
Figure 6. Inhibition of ROS production by impairing complex I or II activity or 870	
by dissipating the membrane potential limits IL-1β production in LPS-activated 871	
macrophages.  872	
(A, C-E) BMDMs were pretreated for 3 h with dimethyl malonate (DMM; 10 mM; A), 873	
carbonylcyanide m-chlorophenylhydrazone (CCCP; 7.5 µM; D), or rotenone (Rot; 0.5 874	
µM; E) before being stimulated with LPS (1 µg/ml; A, E, F) for 24 h (A, E, F) or 4 h 875	
(D), or were treated with succinate (Suc; 1 - 5 mM) for 24 h (B). Live cells were 876	
analyzed by FACS and mean fluorescence intensity (MFI) was quantified as a 877	
measure of cellular reactive oxygen species production. (B, F, G, H, I) BMDMs were 878	
pretreated with MitoQ (500 nM) or MitoTEMPO (Mt.T; 0.5 - 1 mM) for 1 h prior to the 879	
addition of succinate (Suc; 5 mM) for 3 h before stimulation with LPS (100 ng/ml) for 880	
48 h (B). BMDMS were also pretreated for 3 h with rotenone (Rot; 0.1 – 1 µM; F, G) 881	
prior to stimulation with LPS (100 ng/ml) for 24 h. (I – N) Wild-type and AOX-882	
expressing BMDMs were untreated (Ctl) or pretreated for 3 h with succinate (Suc; 5 883	
mM; I, M) before being stimulated with LPS (100 ng/µl; I, K-M or 1 µg/ml; J ) for 48 h. 884	
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Whole cell lysates were analyzed by Western blotting for pro-IL-1β, HIF-1α, β-actin 885	
and AOX (B, G, I, M). mRNA was extracted from total cell lysates and analyzed by 886	
qPCR for IL-1β expression (F). Supernatants were analyzed by ELISA for TNF-α 887	
production (H). Live cells were analyzed by FACS and mean fluorescence intensity 888	
(MFI) was quantified as a measure of cellular reactive oxygen species production (J) 889	
or cells were costained with TMRM (20 nM) and MitoTracker Green (50 nM) for 30 890	
min and then analyzed by FACS to quantify the membrane potential (K, L). The 891	
intensity of TMRM staining reflects the membrane potential. The cytometric dot plots 892	
in (L) are representative from 5 independent experiments. (N) Wild-type (WT) and 893	
alternative oxidase (AOX)-expressing mice were injected i.p. with LPS (10 mg/kg); 894	
survival rate was monitored. AOX group n=11, WT group n=12. The data in (A, C – 895	
F, H) represents mean ± S.E.M., n=3, or n=5 for (J, K) *p<0.05, **p < 0.01, ***p < 896	
0.001. The blots in (B, G, I, M) are representative of 3 independent experiments. See 897	
also Supplemental Figure 6. 898	
 899	
Figure S1. The effect of other Krebs cycle metabolites on LPS-induced 900	
cytokine production. 901	
BMDMs were pretreated with a range of TCA cycle metabolites (succinate, Suc, 5 902	
mM; α-ketoglutarate, αKG, 1 mM; citrate, Cit, 10 mM; pyruvate, Pyr, 5 mM; fumarate, 903	
Fum, 25 µM) or diethyl butylmalonate (DEBM; 1 mM) for 3 h prior to stimulation with 904	
LPS (100 ng/ml) for 48 h. Whole cell lysates were analyzed by Western blotting for 905	
pro-IL-1β and β-actin (B, E). mRNA was extracted from total cell lysates and 906	
analyzed by qPCR for IL-1β (A, D) expression. Supernatants were analyzed by 907	
ELISA for IL-10 (C, F) and TNF-α production (C,F). The data in (A, C – D, F) 908	
represent mean ± S.E.M., n=3, *p=0.05, **p < 0.01, ***p < 0.001. The blots in (B, E) 909	
are representative of 3 independent experiments. Related to Figure 1. 910	
 911	
Figure S2. The effects of succinate may be HIF-1α-dependent but are 912	
independent of cMyc and IL-10. 913	
BMDMs were pretreated with succinate (Suc; 5 mM) then stimulated with LPS (100 914	
ng/ml) for 48 h (A-C) and oxygen consumption rate (OCR) and proton production rate 915	
(PPR) were analyzed as read-outs for for oxidative phosphorylation and glycolysis, 916	
respectively, using the Seahorse XF-24. The ATP/ADP ratio in cell lysates was 917	
determined using an ATP/ADP assay kit (C). BMDMs were pretreated with a range of 918	
TCA cycle metabolites (succinate, Suc, 5 mM; α-ketoglutarate, αKG, 1 mM; citrate, 919	
Cit, 10 mM; pyruvate, Pyr, 5 mM; fumarate, Fum, 25 µM) or with dimethyloxalylglcine 920	
(DMOG; 200 µM) for 3 h prior to stimulation with LPS (100 ng/ml) for 48 h (D – G, I, 921	
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K) or 4 h (H). BMDMs were untreated (Ctl) or pretreated with an IL-10 receptor 922	
blocking antibody (IL-10R AB; 10 µg/ml) or the appropriate isotype control (IgG ctl; 923	
10 µg/ml) for 1 h prior to the addition of dimethyl malonate (DMM; 10 mM; J) for 3 h 924	
before stimulation with LPS (100 ng/ml) for 48 h. Whole cell lysates were analyzed 925	
by Western blotting for HIF-1α, pro-IL-1β and β-actin (D, G, K). mRNA was extracted 926	
from total cell lysates and analyzed by qPCR for PHD3 (E), LDHA (F), IL-1β (F), 927	
cMyc (H, I) and CD71 (H, J) expression. The data in (A - C, E, F, H, I, J) represent 928	
mean ± S.E.M., n=3, *p=0.05, **p < 0.01. The blots in (D, G, K) are representative of 929	
3 independent experiments. Related to Figures 1 and 2. 930	
 931	
Figure S3. Succinate and dimethyl malonate alter levels of succinate and 932	
malonate, but not those of other Krebs cycle metabolites, and also impact the 933	
transcriptome in LPS-activated macrophages. 934	
BMDMs were pretreated for 3 h with dimethyl malonate (DMM; 10 mM) or succinate 935	
(Suc; 5 mM) prior to stimulation with LPS (100ng/ml)  for 24 h (A – J). Lysed cells 936	
were analyzed by liquid chromatography-mass spectrometry (LC-MS) to determine 937	
metabolite levels. The data represent mean ± S.E.M., n=3. +p = 0.05, *p < 0.05, **p < 938	
0.01. BMDMs were pretreated with dimethyl malonate (DMM; 10 mM) or succinate (5 939	
mM) for 3 h before being stimulated with LPS (100 ng/µl) for 4 or 48 h (K – M). RNA 940	
was isolated and RNA sequencing was performed to determine genes significantly 941	
down-regulated or up-regulated by DMM (K) or succinate (L) and those that are most 942	
differentially regulated by DMM and succinate (M). The strength of the colour refers 943	
to how strongly up-regulated (red) or down-regulated (blue) the various genes are. 944	
Related to Figures 1, 2 and 3. 945	
 946	
Figure S4. Dissipation of the mitochondrial membrane potential by inhibiting 947	
glycolytic ATP production or by using CCCP decreases LPS-induced IL-1β. 948	
BMDMs were pretreated with 2-deoxyglucose (2DG; 0.5 - 2 mM) before being 949	
stimulated with LPS (100 ng/ml) for 48 h (A – E), or were pretreated with CCCP (1.25 950	
– 40 µM) before stimulation with LPS (100 ng/ml) for 4 h (F, H, I). Whole cell lysates 951	
were analyzed by Western blotting for pro-IL-1β and β-actin (A, H). mRNA was 952	
extracted from total cell lysates and analyzed by qPCR for IL-1β expression (B). 953	
Supernatants were analyzed by ELISA for IL-10 (C, I) and TNF-α (D, J) production. 954	
% cytotoxicity was determined by a LDH release assay using a LDH-based 955	
cytotoxicity assay kit (E, F). The effect of increasing concentrations of CCCP on 956	
oxygen consumption (OCR) was analyzed using a Seahorse XF-24 analyzer (G). (K) 957	
Wild-type and AOX-expressing BMDMs were untreated (Ctl) or stimulated with LPS 958	
	 27	
(1 µg/ml) for 48 h. Live cells were analyzed by FACS and mean fluorescence 959	
intensity (MFI) was quantified as a measure of cellular reactive oxygen species 960	
production. The data in (B – F, I, J) represent mean ± S.E.M., n=3, *p<0.05, **p < 961	
0.01, ***p < 0.001. The blots in (A, H) and the OCR data in (G) are representative of 962	
3 independent experiments. The curves in (K) are representative of 5 independent 963	
experiments. Related to Figure 5. 964	
 965	
Figure S5. Inhibition of ATP synthase with oligomycin decreases LPS-induced 966	
IL-1β. 967	
BMDMs were pretreated with oligomycin (oligo; 1- 10 µM) before being stimulated 968	
with LPS (100 ng/ml) for 48 h (A, B, D, F) or 4 h (C, E). mRNA was extracted from 969	
total cell lysates and analyzed by qPCR for IL-1β (A), IL-10 (C) and TNF-α (E) 970	
expression. Whole cell lysates were analyzed by Western blotting for pro-IL-1β and 971	
β-actin (E). Supernatants were analyzed by ELISA for IL-10 (D) and TNF-α (F) 972	
production. The data in (A, C - F) represent mean ± S.E.M., n=3, *p<0.05, +=0.05. 973	
The blots in (B) are representative of 3 independent experiments. Related to Figure 974	
5. 975	
 976	
Figure S6. The pro-inflammatory activity of succinate is ROS-dependent while 977	
inhibition of complex I or II activity or dissipation of the membrane potential 978	
limits ROS production in LPS-activated macrophages.  979	
BMDMs were untreated (A), treated with succinate (Suc; 1, 5 mM) for 24 h (B) or 980	
pretreated for 3 h with dimethyl malonate (DMM; 10 mM; D), carbonylcyanide m-981	
chlorophenylhydrazone (CCCP; 7.5 µM; E) or rotenone (Rot; 0.5 µM; F) before being 982	
stimulated with LPS (1 µg/ml; D – F) for 24 h. Live cells were analyzed by FACS and 983	
mean fluorescence intensity (MFI) was quantified as a measure of mitochondrial (A) 984	
or cellular (B, D - F) reactive oxygen species production. BMDMs were untreated 985	
(Ctl) or pretreated with N-acetyl cysteine (NAC; 1, 5 mM) for 1 h prior to the addition 986	
of succinate (Suc; 5 mM) for 3 h before stimulation with LPS (100 ng/ml) for 48 h. 987	
Whole cell lysates were analyzed by western blotting for IL-1β, HIF-1α and β-actin. 988	
The data in (A) represents mean ± S.E.M., n=3, **p < 0.01. The curves are 989	
representative of 6 (B) or 3 (D - F) independent experiments. The blots in (C) are 990	
representative of 3 independent experiments. Related to Figure 6. 991	
 992	
Supplementary Table 1. Genes differentially expressed following LPS 993	
treatment. Data shown is normalized expression value of each gene in log2 scale. 994	
	 28	
Fold change (FC) and signal to noise ratio were estimate for LPS versus untreated 995	
control. FDR-adjusted p values ≤ 0.05. Related to Figure 3. 996	
 997	
Supplementary Table 2. Genes differentially expressed by succinate 998	
stimulation in the presence of LPS. Data shown is normalized expression value of 999	
each gene in log2 scale. Fold change (FC) and signal to noise ratio were estimate for 1000	
Succinate+LPS versus LPS. FDR-adjusted p values ≤ 0.05. Related to Figure 3. 1001	
 1002	
Supplementary Table 3. Genes differentially expressed by DMM stimulation in 1003	
the presence of LPS. Data shown is normalized expression value of each gene in 1004	
log2 scale. Fold change (FC) and signal to noise ratio were estimate for DMM+LPS 1005	
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